

REGISTERED BY ME ON

2022/12/22

Mfana Maswanganyi
25/01/2023 13:37:09(UTC+02:00)
Signed by Mfana Maswanganyi,
m.maswanganyi@medicalschemes.co.za

SIGNIFLOW.COM

ANNEXURE F

SPECIALTY MEDICINE TREATMENT BENEFIT

The Specialty Medical Treatment Benefit (SMTB) includes cover for new technology (drugs, devices, and procedures), for which there is acceptable clinical evidence. It is only available to the members on the Essential Plus Option.

The benefit is subject to a limit per person per year, as indicated in Annexure B2, to which all expenses related to the treatment accumulate, with a variable co-payment applicable to all expenses related to this treatment. (If the co-payment is for instance 20%, all accounts related to the admission will pay at 80% of the Scheme Rate.)

Benefits will be extended as follows:

Treatment	Condition	Treatment	Condition
Actemra®	Rheumatoid arthritis	Remsima®	Rheumatoid arthritis Crohn's disease Ulcerative colitis
Amgevita®	Rheumatoid arthritis Crohn's disease Ulcerative colitis	Revellex®	Rheumatoid arthritis Crohn's disease Ulcerative colitis
Blitzima®	Rheumatoid arthritis	Ristova®	Rheumatoid arthritis
Enbrel®	Rheumatoid arthritis	Sensipar®	Chronic renal disease
Entyvio®	Crohn's disease Ulcerative colitis	Simponi® 45mg/0.45ml	Rheumatoid arthritis
Humira®	Rheumatoid arthritis Crohn's disease Ulcerative colitis	Simponi® 50mg/0.5ml	Rheumatoid arthritis Ulcerative colitis
MabThera®	Rheumatoid arthritis	Stelara® 130mg/26ml (Loading Dose)	Crohn's disease
Orencia®	Rheumatoid arthritis	Stelara® 90mg/ml	Crohn's disease
Remiflix®	Rheumatoid arthritis Crohn's disease Ulcerative colitis		

Note: All listed SMTB medicine funds at the Scheme Rate, except for Stelara® 90mg/ml, when used in the treatment of Crohn's disease. In that case a 20% co-payment applies.

PegIntron®	Hepatitis C	20%
Ozurdex®	Retinal vein occlusion	20%
Bariatric Surgery®	Obesity	20%
Balloon Sinuplasty	Chronic sinusitis	20%
HALO oesophageal ablation system	Barrett's oesophagus with high grade dysplasia	0%

In addition, members have access to an overseas Speciality Medical and Technology Benefit as indicated in Annexure B2 of these Rules. All claims will be paid at cost, subject to a 20% co-payment.

This benefit covers international treatment, both in- and out-of-hospital, that is evidence based (clinically sound), but not available in South Africa and which is voluntarily undergone by the patient. Members will be required to fund these costs upfront and will be reimbursed upon their return and subsequent claim against the Scheme, subject to the terms stated above.

Handwritten mark